Navigation Links
Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
Date:1/8/2014

SAN MATEO, Calif., Jan. 8, 2014 /PRNewswire/ -- Labrys Biologics Inc., a biotechnology company focused on treatments for migraine, today announced that patients are now being enrolled in two separate Phase 2b clinical studies of LBR-101 (formerly RN-307) as a subcutaneous once-monthly treatment for the prevention of frequent migraines. The first study is enrolling subjects with chronic migraine, who experience at least 15 headache days per month. The second study is enrolling subjects with high frequency episodic migraine, who experience headaches eight to 14 days per month. 

"Clinical data from six previous clinical studies of LBR-101, as well as emerging evidence of the potential role of anti-CGRP antibodies in the treatment of migraine, supports the expansion of our clinical program to include prevention of high frequency episodic migraine in addition to chronic migraine," said Steven P. James, president and CEO of Labrys Biologics. "Based on results from a recently completed Phase 1 study assessing the subcutaneous delivery of LBR-101, we will be investigating the once-monthly subcutaneous delivery of LBR-101 in both Phase 2 studies, which if successful, should make the product considerably more attractive in medical practice and to patients."

Both studies are multicenter, randomized, double-blind, placebo-controlled, parallel group, multi-dose studies. Approximately 225 and 270 patients are expected to complete the chronic migraine and high frequency episodic migraine studies, respectively.  Subjects will be randomized to receive placebo, a low dose or a high dose treatment once per month for three months. Primary efficacy endpoint for the chronic migraine trial captures the mean change from baseline in the number of hours with headache on the final month of the study (after 12 weeks of treatment). For the high frequency episodic migraine study, the primary endpoint measures the
'/>"/>

SOURCE Labrys Biologics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orthobiologics Market (Allografts, Viscosupplements, DBM, BMP, Stem Cell and Others) is Expected to Reach USD 5,519.9 Million Globally in 2019: Transparency Market Research
2. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
3. Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
4. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
5. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
6. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
7. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
8. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
9. Novartis Group calls on FDA to maintain the well-established naming policy for all biologics to help ensure patient safety
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Oclaro, Inc. (NASDAQ: OCLR ), ... today outlined its complete line of fiber laser solutions ... a leading provider of diodes for industrial fiber laser ... operations, technology expertise and packaging technology to consistently deliver ...
... What:   Investigators from Northwestern ... 510(k) regulatory pathway—through which more than 90% of medical ... study is the most comprehensive survey to date about ... Devices and Radiological Health (CDRH) is currently weighing regulatory ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... It may smell of flatulence and have a reputation for ... dosage, hydrogen sulfide is now being being found to offer ... to stroke, heart attacks and dementia. A new compound (AP39), ... the key to future therapies, by targeting delivery of very ... places inside cells. , Scientists in Exeter have already ...
(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... 80 Million Dogs in U.S. Households - One in ... TV news story on canine cancer by Fox,42 News, ... at http://www.kptm.com ),has generated emotional, heartfelt response and ... new treatments for dogs with cancer,as well as the ...
... of Rutgers University is one of 10 2008 Pew ... Pew Charitable Trusts. Launched in 1991, the Pew Latin ... trained Latin American scientists who show potential for stimulating ... as well as fostering collaboration between scientists in Latin ...
... Group,Inc. (Nasdaq: NYER ) announced that its ... Pharmacy Service Agreement with East Boston,Neighborhood Health Center ... period effective October 6, 2008. Under terms of ... each prescription dispensed in,exchange for providing comprehensive Clinical ...
... Costs for ... India, WEST BEND, Wis., Nov. 12 Anthem ... a new international medical,tourism pilot product that will allow ... designated facilities in India.,Beginning in January 2009, Anthem will ...
... - A novel protein marker has been found that ... regenerate injured liver tissue has the potential for cell-replacement ... of Pennsylvania School of Medicine led by Linda Greenbaum, ... Gastroenterology, have demonstrated that cells expressing the marker can ...
... or President should have an independent health examination to ensure ... today. , Lord David Owen, a trained doctor and ... people are affected by the decisions of people in high ... general public to ensure that their decision making is not ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Announces Pharmacy Service Agreement with East Boston Neighborhood Health Center 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 3Health News:Stem cells with potential to regenerate injured liver tissue identified by Penn researchers 2Health News:World leaders must be more open about their health 2
... PCA Peel® formula, this peel will ... exfoliation for oilier, thicker and more ... on extremely sun damaged and thickened ... those with active/cystic acne and asphyxiated ...
It works by stimulating new growth of skin and collagen by decreasing the bond that holds dead skin cells on the surface. This allows dead cells to be removed gradually, leaving behind a layer of smo...
... LipiVage™ Fat Harvest, Wash & Transfer System ... to make fat transfer procedures simpler for ... satisfy the need for an office-based technique. ... There is no longer a need to ...
... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...
Medicine Products: